View in EDS

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.

Saved in:
Bibliographic Details
Title: Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Authors: Huppert LA; Department of Medicine, University of California San Francisco, San Francisco, USA. Electronic address: Laura.huppert@ucsf.edu., Wolf D; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA., Yau C; Department of Surgery, University of California San Francisco, San Francisco, USA., Brown-Swigart L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA., Hirst GL; Department of Surgery, University of California San Francisco, San Francisco, USA., Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA., Pusztai L; Yale School of Medicine, Yale University, New Haven, USA., Pohlmann PR; Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA., DeMichele A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Shatsky R; Division of Hematology/Oncology, University of California San Diego, San Diego, USA., Yee D; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA., Thomas A; Division of Hematology/Oncology, Duke Cancer Center, Durham, USA., Nanda R; Section of Hematology/Oncology, University of Chicago, Chicago, USA., Perlmutter J; I-SPY2 Research Advocate, Ann Arbor, USA., Heditsian D; I-SPY2 Research Advocate, Ann Arbor, USA., Hylton N; Department of Radiology, University of California San Francisco, San Francisco, USA., Symmans F; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA., Van't Veer LJ; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA., Esserman L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA. Electronic address: https://twitter.com/DrLauraEsserman., Rugo HS; Department of Medicine, University of California San Francisco, San Francisco, USA. Electronic address: https://twitter.com/hoperugo.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2025 Feb; Vol. 36 (2), pp. 172-184. Date of Electronic Publication: 2024 Oct 28.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39477071
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Huppert+LA%22">Huppert LA</searchLink>; Department of Medicine, University of California San Francisco, San Francisco, USA. Electronic address: Laura.huppert@ucsf.edu.<br /><searchLink fieldCode="AU" term="%22Wolf+D%22">Wolf D</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Yau+C%22">Yau C</searchLink>; Department of Surgery, University of California San Francisco, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Brown-Swigart+L%22">Brown-Swigart L</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Hirst+GL%22">Hirst GL</searchLink>; Department of Surgery, University of California San Francisco, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Isaacs+C%22">Isaacs C</searchLink>; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Pusztai+L%22">Pusztai L</searchLink>; Yale School of Medicine, Yale University, New Haven, USA.<br /><searchLink fieldCode="AU" term="%22Pohlmann+PR%22">Pohlmann PR</searchLink>; Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22DeMichele+A%22">DeMichele A</searchLink>; Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.<br /><searchLink fieldCode="AU" term="%22Shatsky+R%22">Shatsky R</searchLink>; Division of Hematology/Oncology, University of California San Diego, San Diego, USA.<br /><searchLink fieldCode="AU" term="%22Yee+D%22">Yee D</searchLink>; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.<br /><searchLink fieldCode="AU" term="%22Thomas+A%22">Thomas A</searchLink>; Division of Hematology/Oncology, Duke Cancer Center, Durham, USA.<br /><searchLink fieldCode="AU" term="%22Nanda+R%22">Nanda R</searchLink>; Section of Hematology/Oncology, University of Chicago, Chicago, USA.<br /><searchLink fieldCode="AU" term="%22Perlmutter+J%22">Perlmutter J</searchLink>; I-SPY2 Research Advocate, Ann Arbor, USA.<br /><searchLink fieldCode="AU" term="%22Heditsian+D%22">Heditsian D</searchLink>; I-SPY2 Research Advocate, Ann Arbor, USA.<br /><searchLink fieldCode="AU" term="%22Hylton+N%22">Hylton N</searchLink>; Department of Radiology, University of California San Francisco, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Symmans+F%22">Symmans F</searchLink>; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Van't+Veer+LJ%22">Van't Veer LJ</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Esserman+L%22">Esserman L</searchLink>; Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA. Electronic address: https://twitter.com/DrLauraEsserman.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; Department of Medicine, University of California San Francisco, San Francisco, USA. Electronic address: https://twitter.com/hoperugo.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2025 Feb; Vol. 36 (2), pp. 172-184. <i>Date of Electronic Publication: </i>2024 Oct 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39477071
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2024.10.018
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 172
    Titles:
      – TitleFull: Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Huppert LA
      – PersonEntity:
          Name:
            NameFull: Wolf D
      – PersonEntity:
          Name:
            NameFull: Yau C
      – PersonEntity:
          Name:
            NameFull: Brown-Swigart L
      – PersonEntity:
          Name:
            NameFull: Hirst GL
      – PersonEntity:
          Name:
            NameFull: Isaacs C
      – PersonEntity:
          Name:
            NameFull: Pusztai L
      – PersonEntity:
          Name:
            NameFull: Pohlmann PR
      – PersonEntity:
          Name:
            NameFull: DeMichele A
      – PersonEntity:
          Name:
            NameFull: Shatsky R
      – PersonEntity:
          Name:
            NameFull: Yee D
      – PersonEntity:
          Name:
            NameFull: Thomas A
      – PersonEntity:
          Name:
            NameFull: Nanda R
      – PersonEntity:
          Name:
            NameFull: Perlmutter J
      – PersonEntity:
          Name:
            NameFull: Heditsian D
      – PersonEntity:
          Name:
            NameFull: Hylton N
      – PersonEntity:
          Name:
            NameFull: Symmans F
      – PersonEntity:
          Name:
            NameFull: Van't Veer LJ
      – PersonEntity:
          Name:
            NameFull: Esserman L
      – PersonEntity:
          Name:
            NameFull: Rugo HS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2025 Feb
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Numbering:
            – Type: volume
              Value: 36
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1